Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 1/2008

01.02.2008

National experience with an electronic medical record for anticoagulation therapy

verfasst von: J. Woyach, M. Wurster

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Excerpt

Introduction Although anticoagulation with warfarin is very common in medical practice, there is great variety in the way anticoagulation therapy is managed, and little is known about optimal management strategies. It has previously been demonstrated that patients in designated anticoagulation clinics have more therapeutic INR measurements than those managed in primary care offices, [13] however many studies are limited by small sample size or single center sampling. There is also great variability among anticoagulation clinics, especially in frequency of INR testing and practitioners managing the clinic. The availability of electronic medical record support for anticoagulation therapy has created a unique opportunity in terms of data analysis and quality assurance. Electronic medical records allow examination of clinical practice on a large scale to assist with the establishment of quality standards and collection of benchmarking data. In this retrospective analysis, we used CoagClinic™ software to examine practice variation in anticoagulation management and the relationship of these variables to INR compliance. Methods System eligibility requirements include a minimum of ten visits per month, and at least one year of continuous use of the application. A total of 130 systems qualified for the study. A total of 1,157,648 encounters involving 119,017 patients were examined. Variables examined included frequency of INR testing, number of providers in the clinic, duration of use of CoagClinic™ software, and scope of practitioner practice. INR compliance rates were calculated using the frequency of results in the therapeutic range and therapeutic range ±0.2. Results Based on the available data, a theoretical “average” anticoagulation clinic would have a patient population of 379 patients and 649 per month, seen by 17 providers in six locations. Nationally, the INR compliance rate utilizing strict range criteria was 52.1%, and 66.3% for INR range ±0.2. Effects on INR compliance rates by factors such as frequency of INR testing, number of providers, duration of clinic activity and type of provider were examined by linear regression analysis or student’s t-test where appropriate. No statistically significant effects by these factors were found with respect to INR compliance rates. Discussion In this analysis, we looked at the variables of testing frequency, number of managing practitioners, duration of use CoagClinic™ software, and primary practitioner scope of practice to determine whether these variables influenced INR compliance. Overall, INR compliance was seen in 66.4% of patient visits (SD = 0.05). This compliance rate was not altered by testing frequency, duration of electronic medical record use, number of providers, or scope of practice of the provider. This suggests that there may be ways to make anticoagulation management more cost-effective, such as decreasing the frequency of INR testing, or establishing more nurse or pharmacist-run clinics, without sacrificing INR compliance. These results also show that nearly 1/3 of patients are found to be out of range of INR compliance at any given time, so there is a need for further investigation in this area to determine whether there are variables which can be adjusted to make anticoagulation management more effective. …
Literatur
1.
Zurück zum Zitat Witt DM, Sadler MA, Shanahan RL, et al (2005) Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 127:1515–1522PubMedCrossRef Witt DM, Sadler MA, Shanahan RL, et al (2005) Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 127:1515–1522PubMedCrossRef
2.
Zurück zum Zitat Chiquette E, Amato MG, Bussey HI (1998) Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 158:1641–1647PubMedCrossRef Chiquette E, Amato MG, Bussey HI (1998) Comparison of an anticoagulation clinic with usual medical care. Arch Intern Med 158:1641–1647PubMedCrossRef
3.
Zurück zum Zitat Wilson SJ, Wells PS, Kovacs MJ, et al (2003) Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 169(4):293–298PubMed Wilson SJ, Wells PS, Kovacs MJ, et al (2003) Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 169(4):293–298PubMed
Metadaten
Titel
National experience with an electronic medical record for anticoagulation therapy
verfasst von
J. Woyach
M. Wurster
Publikationsdatum
01.02.2008
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 1/2008
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0151-4

Weitere Artikel der Ausgabe 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.